Idarucizumab – practical application in 3 clinical cases Case report
Article Sidebar
Main Article Content
Abstract
First-line drugs for anticoagulation therapy in patients with atrial fibrillation are non-vitamin K oral anticoagulants (NOAC). Dabigatran is currently the only representative of NOAC with an antidote registered in Poland (a molecule called idarucizumab) giving the possibility of reversing the anticoagulant effect in case of emergency (life-threatening bleeding or the need for urgent intervention associated with a significant risk of bleeding). Idarucizumab is administered in a dose of 5 g in the form of two vials (2.5 g each in a volume of 50 ml by rapid infusion [5–10 min] i.v., or as a bolus injection). This article presents three clinical cases of the practical application of idarucizumab with comments.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Balsam P., Ozieranski K., Tyminska A. et al.: Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study. Kardiol. Pol. 2018; 76: 889-898. DOI: 10.5603/KP.a2018.0027.
3. Steffel J., Verhamme P., Potpara T.S. et al.: [The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary]. Kardiol. Pol. 2018; 76: 1283-1298. DOI: 10.5603/KP.2018.0180.
4. Ozieranski K., Balsam P., Opolski G.: 12 najczęstszych sytuacji klinicznych związanych ze stosowaniem NOAC u pacjentów z AF po uwzględnieniu wytycznych ESC z 2016 r. Kardiol. Dypl. 2016; 15: 8-28.
5. Praxbind.
6. Tse D.M., Young L., Ranta A. et al.: Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab. J. Neurol. Neurosurg. Psychiatry 2018; 89: 549-550. DOI: 10.1136/jnnp-2017-316449.
7. Kermer P., Eschenfelder C.C., Diener H.C. et al.: Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – a national case collection. Int. J. Stroke 2017; 12: 383-391. DOI: 10.1177/1747493017701944.
8. Wesołowska K., Woronowicz-Chróściel A., Kluk M., Wożakowska-Kapłon B.: Idarucizumab – nowy poziom terapii przeciwkrzepliwej. Opis leczenia powikłań krwotocznych u 93-letniej chorej. Folia Cardiologica 2016; 11(6): 554-556.